Form 4: Cabaletta Bio Director Granted 22,000 Stock Options

Richard C. Henriques Jr., a Director at Cabaletta Bio, Inc., was granted 22,000 stock options with an exercise price of $2.37, set to vest by June 2026 or the next annual meeting.

Summary

• Richard C. Henriques Jr., a Director of Cabaletta Bio, Inc. (CABA), was granted 22,000 stock options on June 9, 2025.
• The exercise price for these options is $2.37 per share.
• The options are for Common Stock and will expire on June 8, 2035.
• The options are set to vest in full upon the earlier of June 9, 2026, or the date of the Corporation's next annual meeting of stockholders.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is generally a positive signal, indicating continued alignment of interests between the board and shareholders, and a commitment to the company's future performance.

Positives

• The grant of stock options to a director aligns management's interests with those of shareholders, incentivizing long-term company performance.
• The exercise price of $2.37 provides a clear benchmark for future stock performance relative to the grant.

Future Outlook

The granted stock options are structured to vest by June 9, 2026, or the date of the next annual meeting, providing a future incentive for the director.

Industry Context

This Form 4 filing represents a routine compensation event for a director, common across publicly traded companies, including those in the biotechnology sector, to incentivize long-term commitment and performance.

Related Party Transactions

• Richard C. Henriques Jr., a Director of Cabaletta Bio, Inc., received a grant of 22,000 stock options, which constitutes a transaction between the company and a related party (a director).

Stakeholder Impact

• Shareholders: The option grant aligns the director's financial interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.

Next Steps

• Vesting of 22,000 stock options upon the earlier of June 9, 2026, or the date of the next annual meeting of stockholders.
• Potential exercise of vested stock options by Richard C. Henriques Jr. before the expiration date of June 8, 2035.

Key Dates

Keywords

Cabaletta Bio, CABA, Stock Options, Insider Transaction, Form 4, Director Compensation, Equity Grant, Biotechnology